Literature DB >> 19925565

Neuromyelitis optica with intraspinal expansion of Schwann cell remyelination.

Hayato Ikota1, Akira Iwasaki, Mitsue Kawarai, Yoichi Nakazato.   

Abstract

We report a case of neuromyelitis optica (NMO) with an unusual pattern of remyelination in the spinal cord. A Japanese woman complained of pain and numbness in the left thumb at the age of 36 years. She mainly presented with optic and spinal symptoms and was initially diagnosed as multiple sclerosis (MS). Her bilateral eyesight decreased, which led to light perception only in the right eye. She became unable to walk without a wheelchair. In spite of steroid pulse therapy, plasma exchange therapy and immunosuppressive therapy, her symptoms gradually worsened. After 33 years of a relapsing-remitting course, she died of septic urinary tract infection at the age of 69 years. Autopsy revealed prominent demyelination in the optic tract and the spinal cord. The optic nerve showed extensive demyelination accompanied by axon depletion. The spinal cord lesions were found in C8 to L2 level (contiguous 15 segments), especially Th5 to Th11 level. The thoracic spinal cord showed extensive remyelination spreading from the entry zone of peripheral nerves to the central portion. Regenerative myelin showed immunopositivity for Schwann/2E, a marker of Schwann cells and myelin of the peripheral nervous system. Expressions of glial fibrillary acidic protein and aquaporin 4 (AQP4) were weakened in the area of Schwann cell remyelination, suggesting that the essential pathogenesis of this case was disturbance of astrocytes. Inhibition of gliosis probably led to cystic cavities, and destruction of basal lamina may have permitted Schwann cells of peripheral nerves to enter the spinal cord and proliferate within empty spaces. Compared with the optic tract and the spinal cord lesions, a large part of the brain plaques was vague and inactive. We pathologically diagnosed this case as NMO for optic neuritis, myelitis, a contiguous spinal cord lesion and loss or decrease of AQP4 expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19925565     DOI: 10.1111/j.1440-1789.2009.01071.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  5 in total

Review 1.  The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.

Authors:  Claudia F Lucchinetti; Yong Guo; Bogdan F Gh Popescu; Kazuo Fujihara; Yasuto Itoyama; Tatsuro Misu
Journal:  Brain Pathol       Date:  2014-01       Impact factor: 6.508

Review 2.  Multiple sclerosis: experimental models and reality.

Authors:  Hans Lassmann; Monika Bradl
Journal:  Acta Neuropathol       Date:  2016-10-20       Impact factor: 17.088

3.  Lack of astrocytes hinders parenchymal oligodendrocyte precursor cells from reaching a myelinating state in osmolyte-induced demyelination.

Authors:  Melanie Lohrberg; Anne Winkler; Jonas Franz; Franziska van der Meer; Torben Ruhwedel; Nikoloz Sirmpilatze; Rakshit Dadarwal; Ronja Handwerker; Daniel Esser; Kerstin Wiegand; Christian Hagel; Andreas Gocht; Fatima Barbara König; Susann Boretius; Wiebke Möbius; Christine Stadelmann; Alonso Barrantes-Freer
Journal:  Acta Neuropathol Commun       Date:  2020-12-24       Impact factor: 7.801

Review 4.  Schwann cell remyelination of the central nervous system: why does it happen and what are the benefits?

Authors:  Civia Z Chen; Björn Neumann; Sarah Förster; Robin J M Franklin
Journal:  Open Biol       Date:  2021-01-27       Impact factor: 6.411

5.  Sera from Patients with NMOSD Reduce the Differentiation Capacity of Precursor Cells in the Central Nervous System.

Authors:  Ulises Gómez-Pinedo; Yolanda García-Ávila; Lucía Gallego-Villarejo; Jordi A Matías-Guiu; María Soledad Benito-Martín; Noelia Esteban-García; Inmaculada Sanclemente-Alamán; Vanesa Pytel; Lidia Moreno-Jiménez; Francisco Sancho-Bielsa; Lucía Vidorreta-Ballesteros; Paloma Montero-Escribano; Jorge Matías-Guiu
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.